Autolus Q2 Revenue Surges 119% to $45.7M; 2026 Guidance Raised to $140–$150M

summarizeSummary

Autolus reported Q2 2026 AUCATZYL revenue of $45.7 million, up 119% year-over-year, and raised full-year guidance to $140–$150 million. Gross margin improved sharply to 55%, and cash runway extends into Q2 2028.

check_boxKey Events · Earnings and Guidance · AUTL

• Q2 Revenue Beat

  Net product revenue reached $45.7 million, up 119% year-over-year and 74% sequentially, driven by deeper penetration in existing U.S. treatment centers and expansion into new centers.

• FY 2026 Guidance Raised

  Full-year AUCATZYL net product revenue guidance was increased to $140–$150 million from $120–$135 million, reflecting strong launch momentum and commercial execution.

• Gross Margin Inflection

  Gross margin hit 55% in Q2 2026, up from 6% in Q1 2026, driven by higher volumes and cost reduction initiatives; management expects peak margins of 65–70%.

• Cash Runway Extended

  With $201.6 million in cash and marketable securities at June 30, 2026, plus $100 million from the recently closed credit facility, operations are funded into Q2 2028.

auto_awesomeAnalysis · AUTL · Life Sciences

A breakout quarter for Autolus saw AUCATZYL net product revenue surge to $45.7 million, more than doubling year-over-year and beating the prior quarter by 74%. Manufacturing efficiencies drove a dramatic gross margin swing from 6% to 55%, putting the company on a clear path to its 65–70% peak margin target. Confidence in continued launch momentum is reflected in management's decision to raise full-year revenue guidance by $15–$20 million. The cash position, bolstered by a recent $100 million credit facility, now funds operations into Q2 2028, removing near-term dilution risk. Multiple pipeline readouts over the next 18 months — lupus, MS, pediatric ALL — provide additional upside catalysts.